These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6352614)

  • 1. The evaluation of ceftazidime in the treatment of bacterial infections in eighty seriously ill patients.
    Walstad RA; Hellum KB; Svarva PL; Ingram PM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():131-7. PubMed ID: 6352614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime in clinical practice.
    Alestig K; Eilard T; Norrby R; Svensson R; Trollfors B; Brorson JE
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():111-4. PubMed ID: 6225759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime in severe infections: a Swiss multicentre study.
    Francioli P; Clément M; Geroulanos S; von Graevenitz A; Luthy R; Regamey C; Stalder H; Vogt M; Waldvogel FA
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():139-46. PubMed ID: 6225761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime in the therapy of serious Gram-negative bacillary infections.
    Pottage JC; Karakusis PH; Fliegelman RM; Levin S; Trenholme GM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():223-8. PubMed ID: 6352623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime: a new approach in the treatment of moderate and severe infections.
    Abbas AM; Taylor MC; Newby D; Jones RB; Rigby CC; Haste AR; Cantor AM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():147-52. PubMed ID: 6352615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group.
    Principi N; Marchisio P
    J Chemother; 1998 Apr; 10(2):108-13. PubMed ID: 9603635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime, as a single antibiotic, in the treatment of multi-resistant Gram-negative infections in intensive care.
    Gasparetto A; Delogu G
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():171-5. PubMed ID: 6352617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of ceftazidime in Japan.
    Ishibiki K
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():123-30. PubMed ID: 6225760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime treatment in intensive care patients.
    van Dalen R; Muytjens HL; Gimbrère JS
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():189-97. PubMed ID: 6225763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of ceftazidime in internal medicine in Japan.
    Shimada K
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():395-7. PubMed ID: 6225765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime in the treatment of complicated respiratory and urinary tract infections.
    Loebis LH; Williams KJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():59-64. PubMed ID: 6352656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime in clinical practice - a summary.
    Norrby SR
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():405-8. PubMed ID: 6352652
    [No Abstract]   [Full Text] [Related]  

  • 13. A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections.
    Mouton Y; Chidiac C; Humbert G; Leroy J; Veyssier P; Modai J; Bertrand A; Dellamonica P; Micoud M; Stahl JP
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():133-40. PubMed ID: 8150757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open study of the use of ceftazidime in Gram-negative infections.
    Wardle JK; Snow MH; Ingham HR; Selkon JB
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():389-93. PubMed ID: 6352650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime--a new extended-spectrum cephalosporin.
    Gozzard DI; Geddes AM; Farrell ID; Eykyn SJ; Phillips I; Wise R; Brown RM
    Lancet; 1982 May; 1(8282):1152-6. PubMed ID: 6122940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open study of ceftazidime in serious infections due to multiply-resistant bacteria.
    Pechère JC; Delisle R
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():181-8. PubMed ID: 6352619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dosage cefepime as treatment for serious bacterial infections.
    Giamarellou H
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():123-32. PubMed ID: 8150755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complicated urinary tract infections treated with ceftazidime and tobramycin: a comparative study.
    Madsen PO; Frimodt-Møller PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():77-9. PubMed ID: 6352658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections.
    Huang CK; Chen YS; Lee SS; Lin WR; Tsai HC; Lin HH; Wann SR; Chen JY; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2002 Sep; 35(3):159-67. PubMed ID: 12380788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime in the treatment of lower respiratory tract infection.
    Peirce TH; Vig SJ; Ingram PM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():21-5. PubMed ID: 6352621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.